Stemline Therapeutics Inc (STML) Gets a Buy Rating from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc (STML), with a price target of $35. The company’s shares closed yesterday at $11.05.

Selvaraju wrote:

“Our 12-month target is derived from a discounted cash flow (DCF)-based asset value of $1.46B for 15% discount rate, 2% terminal growth rate, and 42M outstanding shares. SL-401 and SL-701 probabilities of approval are 100% and 45%, respectively.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.0% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.33, a 174.5% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $23 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.55 and a one-year low of $7.82. Currently, Stemline Therapeutics Inc has an average volume of 708.7K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts